You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
The investment bank said it expects demand for Fulgent's COVID-19 testing to decline over the next two years.
The investment bank also moved the company's stock price target to $45 from a prior target of $25 and noted several recent acquisitions by Invitae.
The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
The investment bank cut its price target on Quest's shares and noted recently passed legislation that it believes will put pricing pressure on the company.
The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.
Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said.
The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.